Answer
The safety and efficacy of trastuzumab emtansine for breast cancer have not been established in patients under 18 years because there is no relevant use in the paediatric population for this indication.
Sources for this answer
- Kadcyla 100 mg and 160 mg Powder for Concentrate for Solution for InfusionRoche Products Limited · emc · SmPC §4.2 Posology and method of administration · Version 18Document updated
Sources checked